Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

26 Nov 2020

Abstract excerpt

Human telomerase reverse transcriptase (hTERT) is a target antigen for cancer immunotherapy in patients with non-small cell lung cancer (NSCLC). We have tested a novel hTERT vaccine, UV1, designed to give high population coverage. UV1 is composed of three synthetic long peptides containing multiple epitopes identified by epitope spreading data from long-term survivors from previous hTERT vaccination trials....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33324397
DOI: 10.3389/fimmu.2020.572172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung CancerPMID 33324397Read ↗

Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention.Semantic proximity Read ↗

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsSemantic proximity Read ↗

Clinical research progress of telomerase targeted cancer immunotherapy: a literature reviewSemantic proximity Read ↗

Generation of frameshift mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV- 1/GM-CSF in a Phase 1 studySemantic proximity Read ↗

A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.Semantic proximity Read ↗

T cell transcriptional and receptor signatures predict response to telomerase vaccination in prostate cancerSemantic proximity Read ↗

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer patients: Short ReviewSemantic proximity Read ↗

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.Semantic proximity Read ↗

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevanceSemantic proximity Read ↗

Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.Semantic proximity Read ↗

Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.Semantic proximity Read ↗

First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.